Pharmacological strategies for muscular dystrophy
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a fatal, genetic disorder whose relentless progression underscores the urgency for developing a cure. Although Duchenne initiated clinical trials roughly 150 years ago, therapies for DMD remain supportive rather than curative. A paradigm shift towards developing rational therapeutic strategies occurred with identification of the DMD gene. Gene- and cell-based therapies designed to replace the missing gene and/or dystrophin protein have achieved varying degrees of success. However, pharmacological strategies not designed to replace dystrophin per se appear promising, and can circumvent many hurdles hampering gene- and cell-based therapy. Here, we will review present pharmacological strategies, in particular those dealing with functional substitution of dystrophin by utrophin and enhancing muscle progenitor commitment by myostatin blockade, with a view toward facilitating drug discovery for DMD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Membrane organization of the dystrophin-glycoprotein complex
Ervasti, J. M., & Campbell, K. P. (1991) · Cell · doi:10.1016/0092-8674(91)90035-w · Cited by 1,329
Research works printed but not linked: 3
- Duchenne, G. B. A. Recherches sur la paralysie musculaire pseudohypertrophique ou paralysie myo-sclerosique. Arch. Gen. Med. 11, 5–528 (1868).
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw–Hill, New York, 1994).
- Bonifati, M. D. et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344–1347 (2000). · DOI · Paper page
Cited by
Items 201–226 of 226
Effects of Heregulin on Muscle: A Biochemical and Histological Analysis
Moss, N. (2014) · Dominican Scholar (Dominican University of California) · doi:10.33015/dominican.edu/2014.bio.04
Effec ts of Heregulin on Muscle: A Biochemical and Histological Analysis
Scholar, D. (2014)
Micro-engineered skeletal and cardiac muscle for Duchenne muscular dystrophy in vitro models
Zatti, S. (2012) · Padua Research Archive (University of Padova)
Schindl, R., Mayer, K., & Aigner, K. (1975) · PubMed
Brolio, M. P. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2016.tde-12092016-111122
Genetik menschlicher Erkrankungen
Graw, J. (2015) · Springer eBooks · doi:10.1007/978-3-662-44817-5_13 · Cited by 1
Myostatin: Physiology and Applications
Baile, C. A., & Della‐Fera, M. A. (2004) · CRC Press eBooks · doi:10.1201/9781482276664-195
Delineation of Duchenne muscular dystrophy gene therapy using genetically engineered mice
Wasala, N. B. (2016) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/57275
Guerron, A. D., Rawat, R., Sali, A., Spurney, C. F., Pistilli, E. E., Cha, H., Pandey, G. S., Gernapudi, R., Francia, D., Farajian, V., et al. (2010) · PLoS ONE · doi:10.1371/annotation/a8a69b21-6156-4ea4-9a66-7a5f7410d760
Das menschliche Genom — Grundlagen menschlicher Vererbung
(2006) · Springer eBooks · doi:10.1007/3-540-29048-6_14
Myostatin: Physiology and Applications
Baile, C. A., Della‐Fera, M. A., Yang, J., & Rayalam, S. (2011) · CRC Press eBooks · doi:10.1081/e-eas2-120045702
Kaplan, K. M., Xiong, Y., Lucerne, A., & Morgan, K. G. (2025) · GeroScience · doi:10.1007/s11357-025-01947-5
Genetik menschlicher Erkrankungen
Ehrenhofer‐Murray, A. E. (2025) · Springer eBooks · doi:10.1007/978-3-662-70328-1_13
Lorant, J. (2016) · theses.fr (ABES) · doi:10.70675/87808109zf52cz4402z9da6z81f59cf2d98e · Cited by 1
Characterization of the dystrophic muscle by ²³Na NMR and ¹H NMR T₂ spectrum
Gerhalter, T. (2018) · theses.fr (ABES) · doi:10.70675/d7ddb629z3f9fz436bz96bezd0b545bdf370
Dynamique et mécanique de complexes dystrophine-actine-lipides membranaires
Mias‐Lucquin, D. (2018) · theses.fr (ABES) · doi:10.70675/091e2702zc85fz4c91z908cz7e654aa5a3de
Cell penetrating and interfering peptides as new cancer therapy
Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3
Bogdanovich, S., Pistilli, E. E., & Khurana, T. S. (2026) · Muscles · doi:10.3390/muscles5030058
Self-citationGomes, J. P. D. A. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.41.2014.tde-16012015-150237
Metadata
- Authors
- Khurana, T. S., & Davies, K. E.
- Affiliations
- University of Pennsylvania (US)
- University of Oxford (GB)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-05-01
- Volume
- 2
- Issue
- 5
- Pages
- 379-390
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2090269652
- Cited by
- 225
- References
- 139
- Citations by year
- 2026: 1 · 2025: 4 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 10 · 2012: 11
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Muscular Dystrophy Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- Duchenne muscular dystrophy, pharmacotherapy, dystrophin, utrophin, muscle progenitor cells, gene therapy, cell therapy, drug discovery, muscle regeneration
- MeSH terms
- Animals, Calcium, Cytoskeletal Proteins, Disease Models, Animal, Drug Evaluation, Preclinical, Homeostasis, Humans, Membrane Proteins, Muscular Dystrophies, Promoter Regions, Genetic, Drug Design, Dystrophin, Utrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.